Infinity Pharmaceuticals Inc.

1.25-0.0300-2.34%Vol 146.19K1Y Perf -66.75%
Jan 21st, 2022 10:01 DELAYED
BID1.24 ASK1.25
Open1.26 Previous Close1.28
Pre-Market1.28 After-Market-
 - -%  - -
Target Price
9.71 
Analyst Rating
Strong Buy 1.00
Potential %
664.57 
Finscreener Ranking
★★★     48.71
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     40.42
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     36.69
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.00 
Earnings Rating
Strong Buy
Market Cap111.27M 
Earnings Date
15th Mar 2022
Alpha0.01 Standard Deviation0.27
Beta1.94 

Today's Price Range

1.251.31

52W Range

1.255.98

5 Year PE Ratio Range

-3.90-3.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-10.49%
1 Month
-52.24%
3 Months
-51.70%
6 Months
-52.94%
1 Year
-66.75%
3 Years
3.23%
5 Years
-36.00%
10 Years
-87.16%

TickerPriceChg.Chg.%
INFI1.25-0.0300-2.34
AAPL163.56-0.9500-0.58
GOOG2 657.45-12.6800-0.47
MSFT299.03-2.5700-0.85
XOM71.46-1.8100-2.47
WFC54.01-0.9900-1.80
JNJ167.372.12001.28
FB312.28-4.2800-1.35
GE97.27-0.9800-1.00
JPM146.54-1.1200-0.76
Financial StrengthValueIndustryS&P 500US Markets
7.30
7.40
0.61
1.60
-55.80
Leverage Ratio 2.50
ProfitabilityValueIndustryS&P 500US Markets
39.70
-2 356.60
-2 330.60
-1 403.20
-
RevenueValueIndustryS&P 500US Markets
1.41M
0.02
-55.69
-40.67
Earnings HistoryEstimateReportedSurprise %
Q03 2021-0.14-0.1214.29
Q02 2021-0.13-0.130.00
Q01 2021-0.14-0.15-7.14
Q04 2020-0.16-0.17-6.25
Q03 2020-0.15-0.16-6.67
Q02 2020-0.20-0.1620.00
Q01 2020-0.09-0.19-111.11
Q04 2019-0.19-0.20-5.26
Earnings Per EndEstimateRevision %Trend
12/2021 QR-0.140.00-
12/2021 FY-0.535.36Positive
3/2022 QR-0.156.25Positive
12/2022 FY-0.64-4.92Negative
Next Report Date15th Mar 2022
Estimated EPS Next Report-0.14
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume146.19K
Shares Outstanding89.02M
Shares Float87.10M
Trades Count410
Dollar Volume257.42K
Avg. Volume1.59M
Avg. Weekly Volume784.54K
Avg. Monthly Volume1.43M
Avg. Quarterly Volume1.58M

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) stock closed at 1.28 per share at the end of the most recent trading day (a 0.79% change compared to the prior day closing price) with a volume of 1.20M shares and market capitalization of 111.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Infinity Pharmaceuticals Inc. CEO is Adelene Q. Perkins.

The one-year performance of Infinity Pharmaceuticals Inc. stock is -66.75%, while year-to-date (YTD) performance is -43.11%. INFI stock has a five-year performance of -36%. Its 52-week range is between 1.25 and 5.98, which gives INFI stock a 52-week price range ratio of 0.00%

Infinity Pharmaceuticals Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 3.96, a price-to-sale (PS) ratio of 90.47, a price to cashflow ratio of 8.50, a PEG ratio of 2.32, a ROA of -62.72%, a ROC of -71.48% and a ROE of -485.88%. The company’s profit margin is -%, its EBITDA margin is -2 330.60%, and its revenue ttm is $1.41 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Infinity Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Infinity Pharmaceuticals Inc.’s next earnings report date is 15th Mar 2022.

The consensus rating of Wall Street analysts for Infinity Pharmaceuticals Inc. is Strong Buy (1), with a target price of $9.71, which is +664.57% compared to the current price. The earnings rating for Infinity Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Infinity Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Infinity Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.43, ATR14 : 0.16, CCI20 : -84.51, Chaikin Money Flow : -0.50, MACD : -0.29, Money Flow Index : 15.49, ROC : -46.67, RSI : 26.50, STOCH (14,3) : 1.74, STOCH RSI : 0.13, UO : 24.74, Williams %R : -98.26), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Infinity Pharmaceuticals Inc. in the last 12-months were: Norman C. Selby (Option Excercise at a value of $4 600)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (100.00 %)
7 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Infinity Pharmaceuticals Inc.

Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.

CEO: Adelene Q. Perkins

Telephone: +1 617 453-1000

Address: 1100 Massachusetts Avenue, Cambridge 02138, MA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

65%35%

News

Stocktwits